NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Pratteln, Switzerland, February 24, 2021 - Santhera Pharmaceuticals
German
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.
Pivotal 6-month data readout for vamorolone in Duchenne muscular dystrophy (DMD) expected in the second quarter of 2021
Organization streamlined with a focus on cost savings and progressing vamorolone
Preliminary unaudited result for 2020: net sales CHF 15.0 million; net loss CHF 71.2 million; cash on hand as of December 31, 2020, CHF 12.4 million
Upsized financing from fund managed by Highbridge Capital Management, LLC (an existing investor in the Company), to satisfy liquidity needs through the next value-inflection point
Further strengthening of Santhera’s capital structure through a proposed convertible bond restructuring supported by its largest convertible bondholder representing approx. 32% of total bonds outstanding
Santhera Pharmaceuticals Holding AG: Santhera Announces Corporate Update and Proposal to Strengthen Capital Structure
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.
Pivotal 6-month data readout for vamorolone in Duchenne muscular dystrophy (DMD) expected in the second quarter of 2021
Organization streamlined with a focus on cost savings and progressing vamorolone
Preliminary unaudited result for 2020: net sales CHF 15.0 million; net loss CHF 71.2 million; cash on hand as of December 31, 2020, CHF 12.4 million
Upsized financing from fund managed by Highbridge Capital Management, LLC (an existing investor in the Company), to satisfy liquidity needs through the next value-inflection point